Myriad Genetics Reports Fiscal Third-Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
Myriad Genetics (MYGN) Misses Q3 EPS by 10c
May 5, 2020 4:35 PM EDTMyriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.08), $0.10 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $164 million versus the consensus estimate of $167.19 million.
"We saw several signs of improved business progress in the fiscal third-quarter and test... More
